CBT Group for Adolescents With ADHD: a Randomized Controlled Trial
This is the first randomized controlled study that tests the efficacy of a cognitive-behavioral group therapy (CBT) on adolescents with ADHD who were in pharmacological treatment but still presented persistent symptoms.
Attention Deficit Hyperactivity Disorder
Drug: Psychopharmacological treatment
Behavioral: CBT group
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
|Official Title:||Group Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: a Randomized Multicenter Controlled Trial|
- Post-treatment ADHD symptoms [ Time Frame: Post-treatment (after receiving 3 month treatment) ] [ Designated as safety issue: No ]measured by ADHD Rating Scale (clinician-administered version for the adolescent and also parent informant). It is a 18 item scale which assesses the diagnostic criteria for ADHD and rates the frequency of each item on a 4 point Likert scale.
- Post-treatment functional impairment [ Time Frame: Post-treatment (after receiving 3 month treatment) ] [ Designated as safety issue: No ]Assessed by Weiss Functional Impairment Scale (WFIRS) self report and parent version (an appropriate measure for functional impairment associated with ADHD) and by GAF (Global Assessment of Functioning) evaluated by a blinded rater. It is a clinician-administered measure to assess clinical severity and functioning.
- Post-treatment depression symptoms [ Time Frame: Post-treatment (after receiving 3 month treatment) ] [ Designated as safety issue: No ]assessed by Beck Inventory Depression Scale (BDI). It is a 21 item scale to test depression symptoms where respondents rate how they have been feeling during the past week on a 4 point Likert scale (0-3)
- Post-treatment anxiety symptoms [ Time Frame: Post-treatment (after receiving 3 month treatment) ] [ Designated as safety issue: No ]assessed by State-Trait Anxiety Inventory. It is a 40 item scale. It differentiates between the temporary condition of "state anxiety" and the more general and long-standing quality of "trait anxiety".
- Post-treatment anger management [ Time Frame: Post-treatment (after receiving 3 month treatment) ] [ Designated as safety issue: No ]State-Trait Anger Expression Inventory-2 (STAXI-2)was used for patients between 16-21 years and STAXI-NA for 15 years-old patients. The STAXI-2 is a self-report questionnaire that measures state anger, trait anger, expression and control of anger
|Study Start Date:||April 2012|
|Study Completion Date:||May 2014|
|Primary Completion Date:||March 2014 (Final data collection date for primary outcome measure)|
Experimental: CBT group
This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
|Behavioral: CBT group|
Active Comparator: Psychopharmacological treatment
Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.
Drug: Psychopharmacological treatment
methylphenidate or atomoxetine
A multicenter, randomized rater-blinded controlled trial was carried out in a sample of 119 adolescents (15-21 years) and was conducted between April 2012- May 2014. Patients were randomly assigned to 12 group manualized cognitive-behavioural group therapy sessions (n=45) or a waiting list control group (N=44). Primary outcomes were assessed by a blind evaluator (ADHD Rating Scale, Clinical Global Impression Scale for Severity, Global Assessment Functioning) before and after treatment as well as by self-report and parent informant ratings.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02172183
|Hospital Universitari Vall d'Hebron|
|Barcelona, Spain, 08035|
|Principal Investigator:||Raquel Vidal, PhD||Hospital Universitari Vall d'Hebron|